A low risk of Candida infections with ixekizumab (IXE); integrated analysis of 25; Candida infx rates - PsO:1.9/100 PY (N  6892); PsA 2.0/100 PY (N 1401); axSpA 1.2/100PY (N 932). Most occured only once, were mild/moderate & were oral or genital Candida https://t.co/ZkkPoSzPMW https://t.co/VysnaQ8rpi